Quick Answer
Amylyx Pharmaceuticals, Inc. reported Operating Income of -$153.29 million for fiscal year 2025.
Amylyx Pharmaceuticals, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$153.29M | +51.3% |
| 2024 | -$314.73M | -911.1% |
| 2023 | $38.80M | +119.3% |
| 2022 | -$201.34M | -143.5% |
| 2021 | -$82.69M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$36.03M | +52.4% | +15.9% |
| June 30, 2025 | -$42.86M | +43.8% | -13.4% |
| March 31, 2025 | -$37.80M | +69.0% | +50.0% |
| September 30, 2024 | -$75.66M | -504.2% | +0.8% |
| June 30, 2024 | -$76.29M | -477.6% | +37.5% |
| March 31, 2024 | -$122.13M | -5848.9% | -752.4% |
| September 30, 2023 | $18.72M | +134.2% | -7.3% |
| June 30, 2023 | $20.20M | +137.2% | +1084.0% |
- Amylyx Pharmaceuticals, Inc. showed an increase of +51.3% in Operating Income compared to the prior fiscal year.
- Over the 2021–2025 period, Amylyx Pharmaceuticals, Inc.’s operating income has declined by 85.4% (from -$82.69 million to -$153.29 million).
- The most recent figure is from Amylyx Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 3, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: